latozinemab
Monoclonal antibody
Evidence outlook · program status
Discontinued (2025-10), after a negative readout
INFRONT-3 missed its clinical co-primary endpoint (October 2025); Alector abandoned latozinemab in FTD-GRN and GSK ended the alliance. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04374136 NCT04374136 · Frontotemporal Dementia Registry: NCT04374136 | 3 | Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo as Measured by the CDR® Plus NACC FTLD-SB in Symptomatic Patients (Through study completion, on average up to 96 weeks); Part 1 Double Blind (Co-Primary US Endpoint) - Evaluation of the Treatment Effect of AL001 Compared With Placebo as Measured by Pharmacodynamic and Disease Pathology Biomarkers in Symptomatic Patients (Baseline to 96 weeks); Part 2 OLE - To Assess the Long-term Safety and Tolerability of AL001 in Participants Who Have Completed Part 1 of the Study (96 weeks) 2025-09-01 | Did not meet the clinical co-primary endpoint of slowing FTD-GRN progression (topline 21 October 2025) | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
1 other tracked programme targets this mechanism, none of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Latozinemab: this drug | Discontinued | Monoclonal antibody | Sortilin | not yet graded | No reviewed efficacy summary | |
| Nivisnebart | Discontinued | Monoclonal antibody | Sortilin | not yet graded | No reviewed efficacy summary |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent